Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:
“Colorectal Cancer Alliance medical advisor Christopher Lieu and colorectal cancer patient Michelle Cappel participated in a Satellite Media Tour to raise awareness about biomarker testing when deciding on colorectal cancer treatment.
Biomarkers are critical to understanding colorectal cancer and targeted treatment options. They help guide diagnosis, predict disease progression, and inform treatment decisions. The more we understand these markers, the more we can move toward truly personalized care that meets each patient’s unique needs.
At the Colorectal Cancer Alliance we understand that knowing your biomarkers can be life-changing. That is why, as part of our Project Cure CRC initiative, we are investing in a biomarker study focused on improving awareness, knowledge, and access to biomarker testing through a combination of health communication strategies and quality improvement initiatives.
By driving conversations about biomarkers and expanding access to testing, we are helping patients and providers make informed decisions, accelerating progress in precision colorectal cancer care and improving patient outcomes.
Learn more from Dr. Lieu and Michelle in this segment from the Satellite Media tour.
More posts featuring Michael Sapienza.